Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Samuel J. Yates, Julian J. Weiss, Abigail Sneider, Emily Geramita, Guru Subramanian Guru Murthy, Talha Badar, Annie Im, Chenyu Lin, Wei Cheng, Eric S. Winer, Yasmin Abaza, Mark R. Litzow, Ehab L. Atallah, Alok Swaroop, Anand Ashwin Patel, Rory M. Shallis

Blood (2024) 144 (Supplement 1): 447.

https://doi.org/10.1182/blood-2024-207116

Published: 2024

Journal Articles

Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors

Blood (2024) 144 (Supplement 1): 1787.

https://doi.org/10.1182/blood-2024-197898

Published: 2024

Journal Articles

CNS Status at Diagnosis Can Identify Acute Myeloid Leukemia Patients with Poor Induction Outcomes

Kristine Broge-Reynen, Emily Giever, Aniko Szabo, Ryan Conrardy, Nicole M Held, Laura C. Michaelis, Lyndsey Runaas, Sameem Abedin, Guru Subramanian Guru Murthy, Karen-Sue Carlson, Ravi Kishore Narra, Sumana Devata, Sheila Swartz, Valarie Ehrlich, Mary Rodgers, Allison Johnson, Ehab L. Atallah

Blood (2024) 144 (Supplement 1): 5173.

https://doi.org/10.1182/blood-2024-208834

Published: 2024

Journal Articles

Next-Generation Sequencing-Based T-Cell Receptor (TR) Measurable Residual Disease Monitoring Does Not Predict Relapse in T-Lineage Acute Lymphoblastic Leukemia

Rafael Madero-Marroquin, Adnan Askari, Yenny Vanegas Moreno, Clare E Anderson, Talha Badar, Guru Subramanian Guru Murthy, Chenyu Lin, Alexander Coltoff, Adam S. Duvall, Richard A. Larson, Olatoyosi Odenike, Wendy Stock, Anand Ashwin Patel, Caner Saygin

Blood (2024) 144 (Supplement 1): 5937.

https://doi.org/10.1182/blood-2024-203665

Published: 2024

Journal Articles

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Blood (2024) 144 (Supplement 1): 3206.

https://doi.org/10.1182/blood-2024-211623

Published: 2024

Journal Articles

Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy

Blood (2024) 144 (Supplement 1): 1250.

https://doi.org/10.1182/blood-2024-201997

Published: 2024

Journal Articles

Outcome of Patients with TP53 Mutated Relapsed/Refractory AML with Lintuzumab-Ac225 in Combination with CLAG-M Following Venetoclax Plus Hypomethylating Agent Therapy

Sameem Abedin, Guru Subramanian Guru Murthy, Mehdi Hamadani, Laura C. Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Katelyn Gauger, Avinash Desai, Mary Chen, Patrik Brodin, Kate L Li, Mojisola Rotibi, Umar Sayeed, Alexandra M. Harrington, Ehab L. Atallah

Blood (2024) 144 (Supplement 1): 4258.

https://doi.org/10.1182/blood-2024-201559

Published: 2024

Journal Articles

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with CD38 Expressing Relapsed/Refractory Acute Myeloid Leukemia

Guru Subramanian Guru Murthy, Jessica T. Leonard, Talha Badar, Cecilia Y. Arana Yi, Adam S Duvall, Bijal D. Shah, Arielle Baim, Tyce Kearl, Alexandra M. Harrington, Aniko Szabo, Ehab L. Atallah

Blood (2023) 142 (Supplement 1): 1541.

https://doi.org/10.1182/blood-2023-187721

Published: 2023

Journal Articles

Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies

Blood (2023) 142 (Supplement 1): 3192.

https://doi.org/10.1182/blood-2023-174790

Published: 2023

Journal Articles

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

Guru Subramanian Guru Murthy, Bijal D. Shah, Adam S Duvall, Jessica T. Leonard, Talha Badar, Cecilia Y. Arana Yi, Tyce Kearl, Arielle Baim, Alexandra M. Harrington, Aniko Szabo, Ehab L. Atallah

Blood (2023) 142 (Supplement 1): 4242.

https://doi.org/10.1182/blood-2023-187468

Published: 2023

Journal Articles

Comparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy

Talha Badar, Ehab L. Atallah, Rory M. Shallis, Anand Ashwin Patel, Guilherme Sacchi De Camargo Correia, Aaron D. Goldberg, Antoine Saliba, Jan Philipp Bewersdorf, Adam S Duvall, Danielle Bradshaw, Yasmin Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Vamsi K. Kota, Mark R. Litzow

Blood (2023) 142 (Supplement 1): 592.

https://doi.org/10.1182/blood-2023-184626

Published: 2023

Journal Articles

Outcomes of Patients Treated with Low-Intensity Re-Induction Therapy for Persistent Disease after a Single Intensive Induction Cycle for Newly Diagnosed Acute Myeloid Leukemia (AML)

Sameem Abedin, Skyler Taylor, Guru Subramanian Guru Murthy, Lyndsey Runaas, Laura C. Michaelis, Karen-Sue Carlson, Ehab L. Atallah

Blood (2022) 140 (Supplement 1): 11020–11021.

https://doi.org/10.1182/blood-2022-160416

Published: 2022

Journal Articles

Clinical Outcomes of Patients with TP53 -Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab L. Atallah, Antoine N. Saliba, Rory Michael Shallis, Maximilian F. Stahl, Jan Philipp Bewersdorf, Guillerhme Sacchi De Camargo Correia, Anand Ashwin Patel, Yasmin Abaza, Guru Subramanian Guru Murthy, Adam S Duvall, Madelyn Burkart, Neil Palmisiano, Danielle Bradshaw, Vamsi K. Kota, Shira Dinner, Aaron D Goldberg, Mark R. Litzow

Blood (2022) 140 (Supplement 1): 6058–6060.

https://doi.org/10.1182/blood-2022-163795

Published: 2022

Journal Articles

Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features

Sameem Abedin, Guru Subramanian Guru Murthy, Aniko Szabo, Mehdi Hamadani, Laura C. Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Katelyn Gauger, Avinash G Desai, Mary M Chen, Alexandra M. Harrington, Ehab L. Atallah

Blood (2022) 140 (Supplement 1): 157–158.

https://doi.org/10.1182/blood-2022-157827

Published: 2022

Journal Articles

Predictors of Long-Term Outcome in TP53 -Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab L. Atallah, Rory Michael Shallis, Antoine N. Saliba, Maximilian F. Stahl, Jan Philipp Bewersdorf, Justin Grenet, Anand Ashwin Patel, Yasmin Abaza, Guru Subramanian Guru Murthy, Adam S Duvall, Madelyn Burkart, Neil Palmisiano, Michal Jakub Kubiak, Vamsi K. Kota, Shira Dinner, Aaron D Goldberg, Mark R. Litzow

Blood (2022) 140 (Supplement 1): 1435–1437.

https://doi.org/10.1182/blood-2022-167731

Published: 2022

Journal Articles

Outcomes of Patients with Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Current Era of Myeloid Therapies

Anand Ashwin Patel, James J. Yoon, Hannah Johnston, Evan C. Chen, Madelyn Burkart, Timothy Seijung Oh, Sunil G. Iyer, Ellen Madarang, Iyana Gross, Terrence Bradley, Yasmin Abaza, Jacqueline S. Garcia, Rory Michael Shallis, Guru Subramanian Guru Murthy, Vikas Gupta, Kristen M. Pettit, John Cursio, Olatoyosi Odenike

Blood (2022) 140 (Supplement 1): 6860–6862.

https://doi.org/10.1182/blood-2022-157603

Published: 2022

Journal Articles

Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia

Blood (2022) 140 (Supplement 1): 5083–5085.

https://doi.org/10.1182/blood-2022-159809

Published: 2022

Journal Articles

Assessment of Comorbidities and Their Association with Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL)Using Various Comorbidity-Based Scoring Systems

Ravi Kishore Narra, Ehab L. Atallah, Laura C. Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Aniko Szabo, Guru Subramanian Guru Murthy

Blood (2022) 140 (Supplement 1): 6035–6036.

https://doi.org/10.1182/blood-2022-165392

Published: 2022

Journal Articles

A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)

Guru Subramanian Guru Murthy, Scott H. Kaufmann, Aniko Szabo, Alexandra M. Harrington, Laura C. Michaelis, Sameem Abedin, Karen Carlson, Lyndsey Runaas, Walter L. Longo, Alexander Hinman, Sonia Maldonado-Schmidt, Althea Thomas, Arielle Baim, Mark R. Litzow, Ehab L. Atallah

Blood (2021) 138 (Supplement 1): 2347.

https://doi.org/10.1182/blood-2021-149351

Published: 2021

Journal Articles

Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia - CIBMTR Analysis

Guru Subramanian Guru Murthy, Brent R. Logan, Stephanie Bo-Subait, Amer Beitingjaneh, Steven Devine, Nosha Farhadfar, Lohith Gowda, Shahrukh Hashmi, Hillard Lazarus, Sunita Nathan, Akshay Sharma, Jean A. Yared, Heather E. Stefanski, Michael A. Pulsipher, Jack W. Hsu, Galen E. Switzer, Sandhya R. Panch, Bronwen E. Shaw

Blood (2021) 138 (Supplement 1): 907.

https://doi.org/10.1182/blood-2021-150635

Published: 2021

NARROW

Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors

CNS Status at Diagnosis Can Identify Acute Myeloid Leukemia Patients with Poor Induction Outcomes

Next-Generation Sequencing-Based T-Cell Receptor (TR) Measurable Residual Disease Monitoring Does Not Predict Relapse in T-Lineage Acute Lymphoblastic Leukemia

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy

Outcome of Patients with TP53 Mutated Relapsed/Refractory AML with Lintuzumab-Ac225 in Combination with CLAG-M Following Venetoclax Plus Hypomethylating Agent Therapy

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with CD38 Expressing Relapsed/Refractory Acute Myeloid Leukemia

Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

Comparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy

Outcomes of Patients Treated with Low-Intensity Re-Induction Therapy for Persistent Disease after a Single Intensive Induction Cycle for Newly Diagnosed Acute Myeloid Leukemia (AML)

Clinical Outcomes of Patients with TP53 -Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features

Predictors of Long-Term Outcome in TP53 -Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Outcomes of Patients with Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Current Era of Myeloid Therapies

Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia

Assessment of Comorbidities and Their Association with Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL)Using Various Comorbidity-Based Scoring Systems

A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)

Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia - CIBMTR Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only